NDRA

Noble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNG Learn why the Virginia Gas Project is positioned to become one of the world's most strategic helium developments as global supply tightens and demand accelerates DALLAS, TX AND ANN ARBOR, MI / ACCESS Newswire / July 17, 2026 / ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webinar featuring Noble Africa, a wholly owned subsidiary of ASP Isotopes and the holding company for Renergen Limited, on Tuesday, July 21, 2026, at 4:15 p.m. ET. The webinar will highlight Noble Africa's proposed merger (the "Proposed Merger" and, together with the related transactions, the "Proposed Transactions") with ENDRA, which, if completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company trading under the ticker symbol "NOBA.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ENDRA Life Sciences Inc. (NASDAQ: NDRA) with Noble Africa LLC. Upon closing of the proposed transaction, ENDRA shareholders are expected to own approximately 3% of the combined company.Halper Sadeh encourages ENDRA shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalp.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an ex.